文献速递眼底病与葡萄膜炎

穹顶状黄斑的高度近视眼脉络膜新生血管治疗反应:两年随访

RESPONSE TO TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN HIGHLY MYOPIC EYES WITH DOME-SHAPED MACULA: Two Years of Follow-Up.
PubMed 文献 · Retina · 2022-01-01

回顾性比较伴或不伴穹顶状黄斑(DSM)的高度近视脉络膜新生血管(CNV)眼接受抗血管内皮生长因子(VEGF)治疗的2年结果。共纳入54眼(54例),其中18眼(33.4%)有DSM。DSM组基线最佳矫正视力显著更高,但3个月后差异消失且未再出现;DSM并非抗VEGF治疗反应的负面预后因素。

要点

  • DSM组基线最佳矫正视力显著高于非DSM组,但3个月后差异消失且未再出现。
  • DSM组CNV位于中心凹的比例为55.6%,非DSM组为83.9%,差异有统计学意义(P=0.033)。
  • 总体而言,DSM不是高度近视CNV抗VEGF治疗2年反应的负面预后因素。

核心结论

  • 总体而言,DSM不是高度近视CNV抗VEGF治疗2年反应的负面预后因素。
  • 在DSM眼中,CNV倾向于位于中心凹外,从而从疾病最早阶段即确保良好的视力预后。

研究设计与样本

  • 回顾性收集未经治疗的近视性CNV且随访2年的数据,根据是否存在DSM分为两组。
  • 在基线、3、12和24个月时获取最佳矫正视力。
  • 评估视力结局与基线CNV类型和面积、巩膜来源供血血管、黄斑萎缩及漆裂纹之间的关联。

主要发现

  • 共纳入54例患者的54眼;18眼(33.4%)有DSM。
  • DSM组10眼(55.6%)CNV位于中心凹,非DSM组30眼(83.9%)位于中心凹,P=0.033。
  • 基线时DSM组平均最佳矫正视力显著高于非DSM组:68.33±12.04 Early Treatment Diabetic Retinopathy Study字母(20/40 Snellen)vs 57.75±13.46 Early Treatment Diabetic Retinopathy Study字母(20/72 Snellen),P=0.007。
  • 该差异在3个月后消失,此后未再出现。
  • 所有其他参数与视力结局均无显著关联。

关键数值与推荐

  • DSM组基线平均最佳矫正视力为68.33±12.04 Early Treatment Diabetic Retinopathy Study字母(20/40 Snellen)。
  • 非DSM组基线平均最佳矫正视力为57.75±13.46 Early Treatment Diabetic Retinopathy Study字母(20/72 Snellen)。
  • DSM组CNV位于中心凹的比例为55.6%(10眼),非DSM组为83.9%(30眼),P=0.033。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the 2-year outcome to antivascular endothelial growth factor therapy for myopic choroidal neovascularization (CNV) in the eyes with or without dome-shaped macula (DSM). METHODS: Data from treatment-naive myopic CNV with a 2-year follow-up were retrospectively collected and divided into two groups according to the presence of DSM. The best-corrected visual acuity was acquired at baseline, 3, 12, and 24 months. The association between visual outcomes and CNV type and area, presence of scleral-derived feeder vessel, macular atrophy, and lacquer cracks at baseline was also evaluated. RESULTS: Fifty-four eyes of 54 patients were included; 18 eyes (33.4%) had DSM. Choroidal neovascularization was foveal in 10 DSM eyes (55.6%) and in 30 non-DSM eyes (83.9%), P = 0.033. At baseline, the mean best-corrected visual acuity was significantly higher in the DSM group (68.33 ± 12.04 Early Treatment Diabetic Retinopathy Study letters, 20/40 Snellen) compared with the non-DSM group (57.75 ± 13.46 Early Treatment Diabetic Retinopathy Study letters, 20/72 Snellen; P = 0.007). This difference disappeared after 3 months and did not reoccur afterward. All other parameters were not significantly associated with visual outcomes. CONCLUSION: Overall, DSM does not represent a negative prognostic factor in response to antivascular endothelial growth factor therapy in myopic CNVs after 2 years. However, in DSM eyes, CNVs tend to be extrafoveal, thus ensuring a good visual prognosis from the earliest stage of the disease.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Pozzo Giuffrida F, Leone G, Mainetti C, et al. RESPONSE TO TREATMENT OF CHOROIDAL NEOVASCULARIZATION IN HIGHLY MYOPIC EYES WITH DOME-SHAPED MACULA: Two Years of Follow-Up. Retina. 2022. PMID: 35174804. doi:10.1097/IAE.0000000000003431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。